Infections related to TNF-α inhibitors

References:

• Furst DE, Breedveld FC, Kalden JE et al. Updated consensus statement on biological agents, specifically tumor necrosis factor α blocking agents and interleukin-1 receptor antagonist, for the treatment of rheumatic diseases, 2005. Ann. Rheum. Dis.64(Suppl. IV), IV2–IV14 (2005).
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JNWM et al. British association of dermatology guidelines for use of biological interventions in psoriasis 2005. Br. J. Derm.153, 486–497 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque type psoriasis. J. Am. Acad. Dermatol.48, 829–835 (2003).
   PubMedGoogle Scholar
• Antoni C, Kruger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis.64, 1150–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Kalb R, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at State University of New York Buffalo. J. Am. Acad. Dermatol.10, 1016 (2005).
   Google Scholar
• Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol.139, 1627–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Van der Stoep A, Fink B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet356, 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyrling S, Lahfa M et al. A global Phase 3 randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br. J. Derm.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Leonardi CL, Goffe BS et al. Etanercept monotherapy in patients with psoriasis: a summary of safety based on an integrated multistudy database. J. Am. Acad. Dermatol.54, S92–S100 (2006).
   Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy CD, Dooley CT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomized controlled trial. Lancet357, 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp KA et al. Infliximab induction and maintenance therapy for moderate-severe psoriasis: a Phase 3 multicentre double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Papp KA. The long term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res.298, 7–15 (2006).
   PubMed Web of Science ®Google Scholar
• Dinarello C. Anticytokine therapeutics and infections. Vaccine21, S24–S34 (2003).
   PubMed Web of Science ®Google Scholar
• Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect. Dis.3, 148–155 (2003).
   PubMed Web of Science ®Google Scholar
• Lin PL, Pawar S, Zinovik A et al. TNF and chemokine expression in granulomas on non-human primates infected with M. tuberculosis. Presented at: Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA 30 September–3 October 2004 (Abstract).
   Google Scholar
• Deepe GS, Gibbons RS. T cells require tumor necrosis factor-α to provide protective immunity in mice infected with Histoplasma capsulatum. J. Infect. Dis.193, 322–330 (2006).
   PubMedGoogle Scholar
• Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology44, 714–720 (2005).
   PubMed Web of Science ®Google Scholar
• Zganiacz A, Santosuosso M, Wang J et al. TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest.113, 401–413 (2004).
   PubMed Web of Science ®Google Scholar
• Netea MG, Radstake T, Joosten LA et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Association with decreased interferon γ production and Toll-like receptor 4 expression. Arthritis Rheum.48, 1853–1857 (2003).
   PubMedGoogle Scholar
• Westhovens R, Yocum D, Han J et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large randomized, placebo-controlled trial (The START trial). Arthritis Rheum.54, 1075–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk if etanercept and infliximab. Semin. Arthritis Rheum.34(Suppl. 1), 34–38 (2005).
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Differences between anti-tumor necrosis factor α monoclonal antibodies and soluble TNF-receptor antagonists in host defense impairment. J. Rheum. Supp.74, 40–47 (2005).
   PubMedGoogle Scholar
• Fleischman R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res. Ther.6(Suppl. 2), S12–S18 (2004).
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O’FallonWM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum.46, 2287–2293 (2002).
   PubMed Web of Science ®Google Scholar
• Hyrich K, Symmons D, Watson K, Silman A and the BSRBR Control Centre. Baseline comorbidity levels in biologic and standard disease modifying anti-rheumatic drug treated patients with rheumatoid arthritis: results from a national patient register. Ann. Rheum. Dis.65, 895–898 (2006).
   PubMed Web of Science ®Google Scholar
• Enbrel Package insert (2005).
   Google Scholar
• Humira Package insert (2005).
   Google Scholar
• Remicade Package insert (2005).
   Google Scholar
• Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut53, 780–782 (2004).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology126, 19–31 (2004).
   PubMed Web of Science ®Google Scholar
• Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut53, 849–853 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin. Gastroenterol. Hepatol.4, 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischman RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med.343, 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP et al. and the TEMPO Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet363, 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann. Rheum. Dis.65, 753–759 (2006).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA295, 2275–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Bassetti S, Wasmer S, Hasler P et al. Staphylococcus aureus carriage in patients with rheumatoid arthritis under conventional and anti-tumour necrosis factor α treatment. J. Rheum.32, 2125–2129 (2005).
   Google Scholar
• Brook I. Secondary bacterial infections complicating skin lesions. J. Med. Microbiol.51, 808–812 (2002).
   PubMedGoogle Scholar
• Giles JT, Bartlett SJ, Gelber AC et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum.55, 333–337 (2006).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Associations with prednisone, disease modifying antirheumatic drugs and anti-tumor necrosis factor therapy. Arthritis Rheum.54, 628–634 (2006).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Beenhower D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis.39, 1254–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Beenhower D. Granulomatous infections associated with tumor necrosis factor antagonists. Clin. Infect. Dis.38, 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. and BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum.52, 1766–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson K, Symmons DPM, Silman AJ and the BSR Biologics Register. Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR Biologics Register. EULAR (2005) (Abstract OP0094).
   Google Scholar
• Tubach F, Salmon-Ceron D, Ravaud P, Mariette X and the RATIO Study Group. The RATIO Observatory: French Registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF α therapy. Joint Bone Spine72, 456–460 (2005).
   PubMedGoogle Scholar
• Listing J, Stranfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum.52, 3403–3412 (2005).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. and the ADEPT study group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52, 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under TNF-α therapy. Rheumatology42, 617–621 (2003).
   PubMed Web of Science ®Google Scholar
• Kirby AC, Raynes JG, Kaye PM. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J. Infect. Dis.191, 1538–1547 (2005).
   PubMedGoogle Scholar
• Harbath S, Garbino J, Pittet D, Pugin J. Is anti-tumor necrosis factor therapy associated with increased mortality in patients with severe sepsis caused by pneumonia. J. Infect. Dis.189, 1743 (2004).
   PubMedGoogle Scholar
• Baeten D, Kruithof E, Van den Bosch F et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann. Rheum. Dis.62, 829–834 (2003).
   PubMed Web of Science ®Google Scholar
• Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum.46, 2255–2257 (2002).
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SL, Lee KH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α neutralizing agents. Arthritis Rheum.48, 319–324 (2003).
   PubMed Web of Science ®Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum.11, 3013–3022 (2003).
   Google Scholar
• Cornillie F, Shealy D, D’Haens G et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol. Ther.15, 463–473 (2001).
   PubMed Web of Science ®Google Scholar
• Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum.50, 3049 (2004).
   PubMed Web of Science ®Google Scholar
• Claudepierre P, Deprez X, Goupille P et al. Club Rheumatismes et Inflammation, French Society of Rheumatology. Anti-TNF α therapy and safety monitoring: clinical tool guide. Joint Bone Spine72(Suppl. 1), S1–S58 (2005).
   PubMedGoogle Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized Phase 3 trial. ATTRACT Study Group. Lancet354, 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum.52, 2968–2974 (2005).
   PubMedGoogle Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum.50, 372–379 (2004).
   PubMed Web of Science ®Google Scholar
• Tuberculosis associated with blocking agents against tumor necrosis factor-α – California, 2002–2003. MMWR53, 683–686 (2004).
   PubMedGoogle Scholar
• Ormerod LP and British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax60, 800–805 (2005).
   PubMedGoogle Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum.48, 2122–2127 (2003).
   PubMed Web of Science ®Google Scholar
• Perez JL, Kupper H, Spencer-Green GT. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. Presented at: Program and Abstracts of the Annual Congress of the European League Against Rheumatism. Vienna, Austria 8–11 June 2005 (Abstract OP0093).
   Google Scholar
• Hernandez-Cruz B, Ponce-de-leon-Rosales S, Sifuentes-Osornio J, Ponce-de-leon-Garduno A, Diaz-Jouanen E. Tuberculous prophylaxis in patients with steroid treatment and systemic rheumatic disease. A case control study. Clin. Exp. Rheumatol.17, 81–87 (1999).
   PubMed Web of Science ®Google Scholar
• Lalvani A, Richeldi L, Kunst H. Interferon γ assays for tuberculosis. Lancet Infect. Dis.5, 322–323 (2005).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/Centers for Diseases Control/Infectious Diseases Society of America. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med.167, 603–662 (2003).
   PubMed Web of Science ®Google Scholar
• Vidal CG, Fernandez SR, Lacasa JM et al. Paradoxical response to antituberculous therapy in infliximab treated patients with disseminated tuberculosis. Clin. Infect. Dis.40, 756–759 (2005).
   PubMedGoogle Scholar
• Narita M, Ashkin D, Hollender E, Pitchenik A. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med.158, 157–161 (1998).
   PubMed Web of Science ®Google Scholar
• Wood KL, Hage CA, Knox KS et al. Histoplasmosis after treatment with anti-TNF therapy. Am. J. Crit. Care Med.167, 1279–1283 (2003).
   Google Scholar
• Hage CA, Wheat LJ, Twigg HL, Knoxx K. Infliximab does not affect dendritic cells’ mediated lymphoproliferative response to Histoplasma capsulatum. Clin. Infect. Dis.41, 1685–1687 (2006).
   Google Scholar
• Smith JG, Williams DM, Graybill JR. Tumor necrosis factor-α plays a role in host defense against Histoplasma capsulatum. J. Infect. Dis.162, 1349–1353 (1990).
   PubMedGoogle Scholar
• Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonist’s infliximab and etanercept. Arthritis Rheum.46, 2565–2570 (2002).
   PubMed Web of Science ®Google Scholar
• Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am. J. Med.112, 78–79 (2002).
   PubMed Web of Science ®Google Scholar
• Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Clin. Infect. Dis.30, 688–695 (2000).
   PubMed Web of Science ®Google Scholar
• Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl. Infect. Dis.4, 148–151 (2002).
   PubMedGoogle Scholar
• McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled double blind study. Clin. Infect. Dis.28, 1049–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum.50, 1959–1966 (2004).
   PubMed Web of Science ®Google Scholar
• Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl. Infect. Dis.5, 3–8 (2003).
   PubMedGoogle Scholar
• Dewsnup DH, Galgiani JN, Graybill JR et al . Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med.124, 305–310 (1996).
   PubMedGoogle Scholar
• Thomas CF, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med.350, 2487–2498 (2004).
   PubMed Web of Science ®Google Scholar
• Ding K, Shibui A, Yang Y, Takamoto M, Matsuguchi T, Sugame K. Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine pneumocystis pneumonia. Microbes Infect.7, 195–203 (2005).
   PubMedGoogle Scholar
• Tai TL, O’Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology41, 951–952 (2002).
   PubMed Web of Science ®Google Scholar
• Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor α therapy with infliximab for Crohn’s disease. Inflamm. Bowel Dis.10, 657–660 (2004).
   PubMed Web of Science ®Google Scholar
• Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor α antagonists. Medicine84, 291–302 (2005).
   PubMed Web of Science ®Google Scholar
• Warris A, Bjorneklett, Gaustad P. Invasive aspergillosis associated with infliximab therapy. N. Engl. J. Med.14, 1099 (2001).
   Google Scholar
• DeRosa FG, Shaz D, Campagna AC, Dellaripa PF, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor α neutralizing antibody: a possible healthcare associated case? Infect Control Hosp. Epidemiol.24, 7 (2003).
   PubMedGoogle Scholar
• Coyle CM, Weis LM, Rhodes LV et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N. Engl. J. Med.351, 42–47 (2004).
   PubMedGoogle Scholar
• Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor α antagonists. Clin. Infect. Dis.37, 838–840 (2003).
   PubMed Web of Science ®Google Scholar
• Uhl EW, Moldawer LL, Busse WW, Jack TJ, Castleman WL. Increased TNF-α gene expression in parainfluenza type 1 (Sendai) virus-induced bronchiolar fibrosis. Am. J. Pathol.152, 513–522 (1998).
   PubMedGoogle Scholar
• Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann. Intern. Med.136, 174 (2002).
   PubMedGoogle Scholar
• Estrach C, Abernethy VE, Dawson JK. Infections and anti-TNF therapy: strategies for screening based on clinical experience. Rheumatology43, 115–116 (2004).
   PubMedGoogle Scholar
• Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn’s disease following anti-tumour necrosis factor therapy. Eur. J. Gastroenterol. Hepatol.14, 1393–1395 (2002).
   PubMed Web of Science ®Google Scholar
• Haerter G, Manfras BJ, de Jong-Hesse Y, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor α antibody therapy for rheumatoid arthritis Clin. Infect. Dis.39, e88–e94 (2004).
   Web of Science ®Google Scholar
• Cottone M, Pietrosi G, Martorana G et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am. J. Gastroenterol.96, 773–775 (2002).
   Google Scholar
• Swindell K, Goldfarb J, Danziger-Isakov L, Sabella C. Herpes zoster after infliximab for Crohn’s disease in adolescent patients . Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA 30 September–3 October 2004 (Abstract 999).
   Google Scholar
• Wolfe F, Michaud K. Rates and risk factors for herpes zoster in patients with rheumatoid arthritis. EULAR (2004) (Abstract OP0149).
   Google Scholar
• Balandraud N, Roudier J, Roudier C. What are the links between Epstein–Barr virus, lymphoma, and tumor necrosis antagonism in rheumatoid arthritis? Semin Arthritis Rheum.34(Suppl. 1), 31–33 (2005).
   PubMedGoogle Scholar
• Esteve M, Saro C, Gonzales-Huix F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut53(9), 1363–1365 (2004).
   PubMed Web of Science ®Google Scholar
• Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis.62, 686–687 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis.63(Suppl. II), II18–II24 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology and microbiology of adjunctive etanercept in HIV-1 associated tuberculosis. AIDS18, 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Grunke M, Dechant C, Antoni C, Junemann A, Holbach LM. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF α-antibody and methotrexate therapy. Am. J. Ophthalmol.134, 270–271 (2002).
   PubMed Web of Science ®Google Scholar
• Mariette X, Salmon D. French Guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis.62, 791 (2003).
   PubMed Web of Science ®Google Scholar
• Ledingham J, Wilkinson C, Deighton C. British Thoracic Society recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology44, 1205–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Orenstein R. Travel in patients receiving TNF-α inhibitors. Travel Med. Infect. Dis.3, 105–109 (2005).
   PubMedGoogle Scholar
• Elkyam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Seminars Arthritis Rheum.33, 283–288 (2004).
   PubMedGoogle Scholar
• Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of disease modifying drugs, including TNF α blockers. Arthritis Rheum.65, 191–194 (2006).
   Google Scholar